Victoria Socha

DocwireNews

During a poster session at the National Kidney Foundation Spring Clinical Meetings 2023, Jamie P. Dwyer, MD, and colleagues reported results of a real-world study designed to examine the impact of sodium zirconium cyclosilicate (SZC) therapy on 3-month medical costs in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi) prior to a diagnosis of hyperkalemia or dispensed SZC fill. The poster was titled Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-term Medical Costs in Hyperkalemia: OPTIMIZE II Study.A large US commercial claims database was used to retrospectively identify patients in the OPTIMIZE II study &ge;18 years of age who were dispensed SZC &ge;60-day supply and continued RAASi between July 2019 and December 2021. Eligible patients had continuous insurance coverage 6 months before (baseline) and 3 months after (follow-up) the index SZC fill.Eligible patients (SZC cohort) were 1:1 exact and propensity-score matched on baseline variables with patients who did not receive SZC and discontinued RAASi following diagnosis of hyperkalemia (non-SZC cohort). The primary outcome of interest was medical costs related to hyperkalemia (any setting and diagnosis position) to payers over 3 months. The researchers also analyzed all-cause medical and pharmacy costs.Each cohort included 467 matched patients. Mean hyperkalemia-related and all-cause medical costs were reduced by $2216 (P=.01) and $6102 (P&lt;.001) per patient, respectively, in the SZC cohort versus the non-SZC cohort. There were also significant reductions in hyperkalemia-related and all-cause inpatient costs and all-cause emergency department costs in the SZC cohort versus the non-SZC cohort. In the SCZ cohort, the reduction in all-cause medical cost offset an increase in all-cause pharmacy cost (mean increase, $3118 per patient; P&lt;.001).In conclusion, the authors said, &ldquo;SZC with continued RAASi therapy was associated with reduced hyperkalemia-related and all-cause medical costs compared with no SZC therapy and RAASi discontinuation after hyperkalemia diagnosis. This suggests potential medical cost savings by adding SZC to maintain RAASi.&rdquo;Source: Dwyer JP, Agiro A, Desai P, Oluwatosin Y. Impact of sodium zirconium cyclosilicate plus renin-angiotensin-aldosterone system inhibitor therapy on short-term medical costs in hyperkalemia: OPTIMIZE II study. Poster #284. Abstract of a poster presented at the National Kidney Foundation Spring Clinical Meetings 2023; April 11-15, 2023; Austin, Texas. Support for the analysis was provided by AstraZeneca.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Costs of SZC Plus RAASi Therapy in Hyperkalemia

Hyperkalemia

Results of a examining the impact of SZC therapy on medical costs in patients receiving RAAS inhibitor therapy prior to a diagnosis of hyperkalemia.

SZC Plus RAASi Therapy in Hyperkalemia

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe